MiMedx to top $400M in revenue by 2018: Lake Street


Lake Street initiates MiMedx (MDXG.PK) at Buy.

The company is set to triple revenue for its wound care product EpiFix and double sales of AminoFix, its soft-tissue repair offering, analysts say.

The company also "has a foundation of strong intellectual property (100+ patents) and is led by an experienced management team with a history of successfully building and selling medical companies."

Ultimately, Lake Street thinks the company can top $400M in revenue and generate $100M in EBITDA "in the next four to five years."

Price target is $7.50.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs